ATU 403, "The Black and the White Bride": a woman, dispised by her (step)family, marries a prince. Later, her step-mother conspires to replace the woman with her (step)sibling. ATU 432, "The Bird Lover" or "The Prince as Bird": a maiden is visited at night by a bird, which is a prince in disguise. Her family  begin to suspect something and set up a trap by her window: they put spikes (nails, broken glass, thorns) to hurt the bird. The bird prince thinks her beloved betrayed him and flees, which prompts the heroine to seek him in parts unknown. ATU 480, "The Kind and Unkind Girls" or "The Spinning-Woman by the Spring": two sisters or stepsisters, one diligent and the other lazy, meet a supernatural entity in the woods or in a magical realm. The diligent sibling acts kindly and obeys the entitys orders, and is rewarded; the lazy one disobeys and is punished. ATU 510A, "Cinderella": the heroine is maltreated by her stepmother and stepsiblings. ATU 511, "One-Eye, Two-Eyes, and Three-Eyes": two women (the first one-eyed and the other three-eyed) mistreat their sibling, a woman with two eyes. ATU 530, "The Princess on the Glass Hill": a father sends his three sons to guard his crops or to hold a vigil on his grave. The older ones disobey and/or feel frightened, so they send their youngest brother, whom they call a fool or stupid, to fulfill their fathers orders.
30% of the clozapine patients responded compared to 4% of the controls, with significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas. Following this study, the US Food and Drug Administration (FDA) approved its use in 1990. Cautious of this risk, however, the FDA required a black box warning for specific side effects including agranulocytosis, and took the unique step of requiring patients to be registered in a formal system of tracking so that blood count levels could be evaluated on a systematic basis.In December 2002, clozapine was approved in the US for reducing the risk of suicide in people with schizophrenia or schizoaffective  judged to be at chronic risk for suicidal behavior. In 2005, the FDA approved criteria to allow reduced blood monitoring frequency. In 2015, the individual manufacturer Patient Registries were consolidated by request of the FDA into a single shared Patient Registry Called The Clozapine REMS Registry. Despite the demonstrated safety of the new FDA monitoring requirements, which have lower neutrophil levels and do not include total white cell counts, international monitoring has not been standardised. Chemistry
Clozapine is a dibenzodiazepine that is structurally very similar to loxapine (originally deemed a typical antipsychotic). It is slightly soluble in water, soluble in acetone, and highly soluble in chloroform. Its solubility in water is 0.1889 mg/L (25 °C). Its manufacturer, Novartis, claims a solubility of <0.01% in water (<100 mg/L).